Enhertu has been approved for pre-treated HER2-low metastatic (secondary) breast cancer in the EU and the USA.
The approval is based on the phase 3 DESTINY-Breast04 trial which showed Enhertu increased the length of time before cancer progressed and overall survival.
The European Commission approval for trastuzumab deruxtecan in HER2-low metastatic breast cancer is based on data from the phase 3 DESTINY-Breast04 trial. #bcsm | @EU_Commission@JavierCortesMDow.ly/f2uo50MCyWT
Thank you for raising awareness of metastatic breast cancer at PMQs. The biggest killer of women aged 30-64. It devastates families.
Research and removal of barriers to access innovative drugs and radiotherapy needed to prevent 31 women a day from dying in the UK.
@METUPUKorg
Please vote for Crooksbarn Primary School. We need to be in the top 40 voters to win £250 for cookery equipment. Every different email address can have 3 votes. venatorcommunity.com/togethe…